MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More

Psychiatry Online · · 1 min read

Clinically Reviewed by Editorial Advisory Panel
depression
MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More

MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More

.

Originally reported by Psychiatry Online. Read more

Source: https://www.psychiatryonline.org/doi/full/10.1176/appi.pn.2026.04.4.3